DCC-3084

DRUG2 trials

Sponsors

Deciphera Pharmaceuticals Inc., Deciphera Pharmaceuticals, LLC

Conditions

Advanced Solid TumorBRAF Gene MutationCRAF Gene MutationCastration-Resistant Prostate Cancer (CRPC)MelanomaNF1 MutationNon-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phase 1

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

TerminatedNCT06287463

Deciphera Pharmaceuticals, LLCAdvanced Solid Tumor, BRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC) +7

Start: 2024-05-14End: 2026-02-13Updated: 2026-03-05

A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway

CompletedCTIS2024-517829-12-00

Deciphera Pharmaceuticals Inc.Solid tumors driven by the MAPK Pathway

End: 2025-09-12Target: 60Updated: 2025-08-18